What's Happening?
The FDA has recently reversed its stance on the use of external controls in clinical trials for rare diseases, creating confusion among biopharma companies. Previously, the FDA had supported the use of natural history external controls for uniQure's Huntington's
disease gene therapy. However, the agency now requires a sham surgery-controlled study. This shift has implications for companies like Stoke Therapeutics and Denali Therapeutics, which are exploring expedited regulatory pathways using external controls. The FDA's guidance encourages innovative trial designs, but the agency's recent actions suggest increased scrutiny on the reliability of external controls.
Why It's Important?
The FDA's changing position on external controls in rare disease trials could significantly impact the biopharma industry. Companies developing treatments for rare diseases often rely on external controls due to the difficulty of enrolling sufficient patients in traditional trials. The increased scrutiny could lead to longer development times and higher costs, potentially delaying the availability of new therapies. This situation underscores the need for clear regulatory guidance and consistent application of policies to support innovation while ensuring patient safety and efficacy of treatments.
What's Next?
Biopharma companies may need to engage more closely with the FDA to align on acceptable trial designs and endpoints. The industry will likely advocate for clearer guidelines and more predictable regulatory processes. Companies may also explore alternative trial designs or additional data sources to meet the FDA's requirements. The outcome of ongoing discussions and trials will shape the future of drug development for rare diseases, influencing how companies approach clinical research and regulatory submissions.
